ClinicalTrials.gg
CompletedNCT00796003Updated Dec 9, 2013Results posted

A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome

A Phase 1 interventional study of JNJ-30979754 15 mg/m2 and JNJ-30979754 20 mg/m2 in Myelodysplastic Syndrome, sponsored by Janssen Pharmaceutical K.K.. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-12-09.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.

Enrollment
40th of 74
39 · median 43
Started
2008
with 5 others
Phase 1
18 of 75
2 open now
Registered
22nd of 75
by date

Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 40th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 18 in phase 1, and was the 22nd registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing decitabine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to to determine the recommended dose level of JNJ-30979754 (decitabine) as well as to assess the safety and effectiveness in patients with Myelodysplastic Syndrome (MDS).

Read the detailed description

This is an open-label (both physician and patient know the name and dosage of drug), multi-center study. This study consists of two parts, Phase I and Phase II. In Phase I, approximately 9 participants will be enrolled ie, 3 participants for dose level 1 (15 mg/m2 of JNJ-30979754) and 6 participants for dose level 2 (20 mg/m2 of JNJ-30979754). Once the tolerability of 20 mg/m2 is confirmed additional 30 participants will be included to receive 20 mg/m2 and approximate total participants in Phase II will be 36. This study will include screening period (within 14 days prior to the day of initial administration of Cycle 1) and dosing period (1 cycle consists of administration of study medication for first 5 consecutive days + rested for 23 days; ie, total 28 days). Cycles will be reapeated in participants in whom decitabine was expected to be effective. Safety evaluations will include assessment of adverse events, vital signs, body weight, clinical laboratory tests: hematology, blood biochemistry and urinalysis, cardiopulmonary function tests: ECG, chest X ray and oximeter analysis.

03

Conditions studied

  • Myelodysplastic Syndrome

Keywords

  • Myelodysplastic syndrome
  • MDS
  • Decitabine
  • JNJ-30979754
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Myelodysplastic syndrome (de novo or secondary) fitting any of the recognized French-American-British classifications: anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia with white blood cells less than 13,000 /mm3
  • International Prognostic Scoring System (IPSS) greater than or equal to 0.5 (Intermediate-1, Intermediate-2 or high risk) by bone marrow assessment and bone marrow cytogenetics within 28 days before study registration
  • 20 years or older
  • (ECOG) performance status of 0-2
  • Normal renal and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Acute Myeloid Leukemia (AML) with bone marrow blasts greater than or equal to 30%
  • Participants with a history of high-dose cytarabine (Ara-C) therapy (greater than 1,000 mg/m2/day)
  • Participants administered adrenal cortex hormones or anabolic hormones within 7 days of study initiation
  • Participants who have received a colony stimulating factor (CSF) formulation within 7 days of study initiation
  • Active double cancer
  • Uncontrolled cardiac disease or cognitive heart failure
  • Uncontrolled restrictive or obstructive pulmonary disease
  • Uncontrolled diabetes mellitus
  • Active viral or bacterial infection
  • Known positive serology for
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Phase I: JNJ-30979754 15 mg/m2

    JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1

    Drug: JNJ-30979754 15 mg/m2

  • Experimental
    Phase I: JNJ-30979754 20 mg/m2

    JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1

    Drug: JNJ-30979754 20 mg/m2

  • Experimental
    Phase II: JNJ-30979754 20 mg/m2

    JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles

    Drug: JNJ-30979754 20 mg/m2

Interventions

  • DrugJNJ-30979754 15 mg/m2

    Drug page: Decitabine

    JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.

    Also known as: decitabine

  • DrugJNJ-30979754 20 mg/m2

    Drug page: Decitabine

    Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.

    Also known as: decitabine

06

What researchers measure

Primary outcomes

  1. Phase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG) Response Criteria (2000)

    IWG response criteria (2000) - CR: bone marrow evaluations show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes.

    Time frame: Up to 1 years after the last participant enrolled

  2. Phase I and II: Number of Participants Who Experienced Adverse Events

    Time frame: Up to 1.5 years after the last participant enrolled

Secondary outcomes

  1. Phase I: Maximum Observed Plasma Concentration of Decitabine (Cmax)

    Time frame: Before dosing (Pre-dose), 30 min, 60 min (end of infusion), 65 min, 75 min, 90 min, 120 min, 180 min, 240 min after the start of decitabine infusion on Day 1 and Day 5 of 28-Days Cycle 1

  2. Phase I: Area Under the Plasma Concentration-time Curve (AUC)

    Area under the curve from time zero to extrapolated infinite time (AUC Infinity) and area under the curve from time zero to last quantifiable concentration (AUC Last).

    Time frame: Before dosing (Pre-dose), 30 min, 60 min (end of infusion), 65 min, 75 min, 90 min, 120 min, 180 min, 240 min after the start of decitabine infusion on Day 1 and Day 5 of 28-Days Cycle 1

  3. Phase I: Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)

    IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia; PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes; HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.

    Time frame: Up to 28 Days of treatment Cycle 1

  4. Phase II: Median Time to Remission

    Median time required for the participants to achieve remission (complete remission+partial remission).

    Time frame: Up to 1.5 years after the last participant enrolled

  5. Phase II: Median Time to Improvement

    Median time required for the participants to achieve overall improvement (complete remission+partial remission+hematologic improvement)

    Time frame: Up to 1.5 years after the last participant enrolled

  6. Phase II: Median Duration of Remission

    Median time duration for which participants achieved remission (complete remission+partial remission).

    Time frame: Up to 1.5 years after the last participant enrolled

  7. Phase II: Median Duration of Overall Improvement

    Median time duration for which participants achieved overall improvement (complete remission+partial remission+hematologic improvement).

    Time frame: Up to 1.5 years after the last participant enrolled

  8. Phase II: Overall Improvement Rate: Number of Participants Who Achieved Complete Response (CR)+Partial Response (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)

    IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes. HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.

    Time frame: Up to 1.5 years after the last participant enrolled

  9. Phase II: Number of Participants With Cytogenic Response - as Per International Working Group (IWG) Response Criteria 2000 (Major/Minor) and IWG 2006 (Complete/Partial)

    IWG 2000 - Major: disappearance of cytogenetic abnormality; Minor: 50% or more reduction in abnormal metaphases. IWG 2006 - Complete: disappearance of the chromosomal abnormality without appearance of new ones; Partial: At least 50% reduction of the chromosomal abnormality.

    Time frame: Up to 1.5 years after the last participant enrolled

07

Results

Posted Dec 9, 2013

Participant flow

39 participants were enrolled at multiple sites in Japan.

Participant flow — Overall Study
MilestonePhase I: 15 mg/m2Phase I and II: 20 mg/m2
Started336
Treated334
Completed07
Not completed329
Withdrew: Disease progression213
Withdrew: Adverse event17
Withdrew: Specified organ function not met01
Withdrew: Physician decision04
Withdrew: Withdrawal by subject01
Withdrew: Other01
Withdrew: Participants not treated02

Outcome measures

PrimaryPhase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG) Response Criteria (2000)

IWG response criteria (2000) - CR: bone marrow evaluations show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes.

Time frame:
Up to 1 years after the last participant enrolled
Reported as:
Number · Participants
Phase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG) Response Criteria (2000)
ParticipantsPhase II: 20 mg/m2
CR7
PR2
Statistical analysis
  • Phase II: 20 mg/m2 · Binomial test · p = <0.0001 · Overall response rate: 26.5 · 90% CI 14.6 to 41.6one-tailed 5% level at a significance level
PrimaryPhase I and II: Number of Participants Who Experienced Adverse Events
Time frame:
Up to 1.5 years after the last participant enrolled
Reported as:
Number · Participants
Phase I and II: Number of Participants Who Experienced Adverse Events
ParticipantsPhase I: 15 mg/m2Phase I: 20 mg/m2Phase II: 20 mg/m2
Phase I and II: Number of Participants Who Experienced Adverse Events3634
SecondaryPhase I: Maximum Observed Plasma Concentration of Decitabine (Cmax)
Time frame:
Before dosing (Pre-dose), 30 min, 60 min (end of infusion), 65 min, 75 min, 90 min, 120 min, 180 min, 240 min after the start of decitabine infusion on Day 1 and Day 5 of 28-Days Cycle 1
Reported as:
Mean · ng/mL
Phase I: Maximum Observed Plasma Concentration of Decitabine (Cmax)
ng/mLPhase I: 15 mg/m2Phase I: 20 mg/m2
Day 1151.7 ± 28.729166.4 ± 17.170
Day 5142.0 ± 40.635190.6 ± 54.679
SecondaryPhase I: Area Under the Plasma Concentration-time Curve (AUC)

Area under the curve from time zero to extrapolated infinite time (AUC Infinity) and area under the curve from time zero to last quantifiable concentration (AUC Last).

Time frame:
Before dosing (Pre-dose), 30 min, 60 min (end of infusion), 65 min, 75 min, 90 min, 120 min, 180 min, 240 min after the start of decitabine infusion on Day 1 and Day 5 of 28-Days Cycle 1
Reported as:
Mean · ng*h/mL
Phase I: Area Under the Plasma Concentration-time Curve (AUC)
ng*h/mLPhase I: 15 mg/m2Phase I: 20 mg/m2
AUC Last - Day 1149.0 ± 41.102155.2 ± 15.754
AUC Last - Day 5136.0 ± 37.855152.0 ± 15.712
AUC Infinity - Day 1150.0 ± 40.777156.1 ± 15.497
AUC Infinity - Day 5136.9 ± 37.897151.2 ± 17.617
SecondaryPhase I: Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)

IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia; PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes; HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.

Time frame:
Up to 28 Days of treatment Cycle 1
Reported as:
Number · Participants
Phase I: Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)
ParticipantsPhase I: 15 mg/m2Phase I: 20 mg/m2
PR11
HI12
SecondaryPhase II: Median Time to Remission

Median time required for the participants to achieve remission (complete remission+partial remission).

Time frame:
Up to 1.5 years after the last participant enrolled
Reported as:
Median · Days
Phase II: Median Time to Remission
DaysPhase II: 20 mg/m2
Phase II: Median Time to Remission130.0 (67.0 to 208.0)
SecondaryPhase II: Median Time to Improvement

Median time required for the participants to achieve overall improvement (complete remission+partial remission+hematologic improvement)

Time frame:
Up to 1.5 years after the last participant enrolled
Reported as:
Median · Days
Phase II: Median Time to Improvement
DaysPhase II: 20 mg/m2
Phase II: Median Time to Improvement26.5 (22.0 to 36.0)
SecondaryPhase II: Median Duration of Remission

Median time duration for which participants achieved remission (complete remission+partial remission).

Time frame:
Up to 1.5 years after the last participant enrolled
Reported as:
Median · Days
Phase II: Median Duration of Remission
DaysPhase II: 20 mg/m2
Phase II: Median Duration of Remission489 (294 to 489)
SecondaryPhase II: Median Duration of Overall Improvement

Median time duration for which participants achieved overall improvement (complete remission+partial remission+hematologic improvement).

Time frame:
Up to 1.5 years after the last participant enrolled
Reported as:
Median · Days
Phase II: Median Duration of Overall Improvement
DaysPhase II: 20 mg/m2
Phase II: Median Duration of Overall Improvement532 (147 to 554)
SecondaryPhase II: Overall Improvement Rate: Number of Participants Who Achieved Complete Response (CR)+Partial Response (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)

IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes. HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.

Time frame:
Up to 1.5 years after the last participant enrolled
Reported as:
Number · Participants
Phase II: Overall Improvement Rate: Number of Participants Who Achieved Complete Response (CR)+Partial Response (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)
ParticipantsPhase II: 20 mg/m2
CR7
PR2
HI5
SecondaryPhase II: Number of Participants With Cytogenic Response - as Per International Working Group (IWG) Response Criteria 2000 (Major/Minor) and IWG 2006 (Complete/Partial)

IWG 2000 - Major: disappearance of cytogenetic abnormality; Minor: 50% or more reduction in abnormal metaphases. IWG 2006 - Complete: disappearance of the chromosomal abnormality without appearance of new ones; Partial: At least 50% reduction of the chromosomal abnormality.

Time frame:
Up to 1.5 years after the last participant enrolled
Reported as:
Number · Participants
Phase II: Number of Participants With Cytogenic Response - as Per International Working Group (IWG) Response Criteria 2000 (Major/Minor) and IWG 2006 (Complete/Partial)
ParticipantsPhase II: 20 mg/m2
Major/Complete6
Minor/Partial1
No response10
Not estimable3

Adverse events

Collected over Up to 1.5 years after the last participant enrolled. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I - 15 mg/m2 Group—1/3 (33.3%)3/3 (100%)
Phase I - 20 mg/m2 Group—1/6 (16.7%)6/6 (100%)
Phase II: 20 mg/m2—11/34 (32.4%)34/34 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPhase I - 15 mg/m2 GroupPhase I - 20 mg/m2 GroupPhase II: 20 mg/m2
PneumoniaInfections and infestations1/30/64/34
CellulitisInfections and infestations0/31/61/34
PharyngitisInfections and infestations0/31/61/34
Febrile neutropeniaBlood and lymphatic system disorders0/31/62/34
Wound complicationInjury, poisoning and procedural complications0/31/61/34
SepsisInfections and infestations0/30/62/34
Neutropenic infectionInfections and infestations0/30/61/34
Pneumonia fungalInfections and infestations0/30/61/34
Enterocolitis viralInfections and infestations0/30/61/34
AneamiaBlood and lymphatic system disorders0/30/61/34
Most frequent other events
Showing 10 of 84
Most frequent other events
EventPhase I - 15 mg/m2 GroupPhase I - 20 mg/m2 GroupPhase II: 20 mg/m2
LeukopeniaBlood and lymphatic system disorders3/36/634/34
AnaemiaBlood and lymphatic system disorders3/36/629/34
LymphopeniaBlood and lymphatic system disorders3/35/629/34
ThrombocytopeniaBlood and lymphatic system disorders3/36/627/34
NeutropeniaBlood and lymphatic system disorders3/35/626/34
C-reactive protein increasedInvestigations3/31/61/34
Blood urine presentInvestigations0/35/611/34
Neutropenic infectionInfections and infestations2/33/615/34
StomatitisGastrointestinal disorders2/33/69/34
Transfusion reactionInjury, poisoning and procedural complications2/31/611/34

Baseline characteristics

For Baseline characteristics analysis, number of participants treated were analyzed (37) instead of number of participants enrolled (39). 2 enrolled participants were not treated.

Age Continuous
Age Continuous(Years)Phase I: 15 mg/m2Phase I and II: 20 mg/m2Total
Mean68.7 ± 2.0868.5 ± 7.0968.5 ± 6.81
Age, Customized
Age, Customized(Participants)Phase I: 15 mg/m2Phase I and II: 20 mg/m2Total
<65 years01010
>= 65 and <= 74 years31720
>=75 years077
Sex: Female, Male
Sex: Female, Male(Participants)Phase I: 15 mg/m2Phase I and II: 20 mg/m2Total
Female088
Male32629
08

Study locations

7 sites
  • Fukuoka, Japan
  • Hamamatsu, Japan
  • Hidaka, Japan
  • Nagasaki, Japan
  • Nagoya, Japan
  • Shinjuku, Japan
  • Tokyo, Japan
09

References and documents

Publications

  • Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M. Phase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in Japan. Cancer Sci. 2012 Oct;103(10):1839-47. doi: 10.1111/j.1349-7006.2012.02386.x. Epub 2012 Sep 14. PubMed 22816487 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2008
First posted
Nov 24, 2008
Start
Jul 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Dec 9, 2013
Last update
Dec 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00796003
Responsible party
Sponsor
First posted
Nov 24, 2008
Start date
Jul 2008
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Dec 9, 2013
Last update
Dec 9, 2013

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion